Cargando…

Naturally Occurring Acetylcholinesterase Inhibitors and Their Potential Use for Alzheimer's Disease Therapy

Alzheimer's disease (AD) is a main cause of dementia, accounting for up to 75% of all dementia cases. Pathophysiological processes described for AD progression involve neurons and synapses degeneration, mainly characterized by cholinergic impairment. This feature makes acetylcholinesterase inhi...

Descripción completa

Detalles Bibliográficos
Autores principales: dos Santos, Thaiane Coelho, Gomes, Thaís Mota, Pinto, Bruno Araújo Serra, Camara, Adriana Leandro, Paes, Antonio Marcus de Andrade
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6201143/
https://www.ncbi.nlm.nih.gov/pubmed/30405413
http://dx.doi.org/10.3389/fphar.2018.01192
_version_ 1783365450273390592
author dos Santos, Thaiane Coelho
Gomes, Thaís Mota
Pinto, Bruno Araújo Serra
Camara, Adriana Leandro
Paes, Antonio Marcus de Andrade
author_facet dos Santos, Thaiane Coelho
Gomes, Thaís Mota
Pinto, Bruno Araújo Serra
Camara, Adriana Leandro
Paes, Antonio Marcus de Andrade
author_sort dos Santos, Thaiane Coelho
collection PubMed
description Alzheimer's disease (AD) is a main cause of dementia, accounting for up to 75% of all dementia cases. Pathophysiological processes described for AD progression involve neurons and synapses degeneration, mainly characterized by cholinergic impairment. This feature makes acetylcholinesterase inhibitors (AChEi) the main class of drugs currently used for the treatment of AD dementia phase, among which galantamine is the only naturally occurring substance. However, several plant species producing diverse classes of alkaloids, coumarins, terpenes, and polyphenols have been assessed for their anti-AChE activity, becoming potential candidates for new anti-AD drugs. Therefore, this mini-review aimed to recapitulate last decade studies on the anti-AChE activity of plant species, their respective extracts, as well as isolated compounds. The anti-AChE activity of extracts prepared from 54 plant species pertaining 29 families, as well as 36 isolated compounds were classified and discussed according to their anti-AChE pharmacological potency to highlight the most prominent ones. Besides, relevant limitations, such as proper antioxidant assessment, and scarcity of toxicological and clinical studies were also discussed in order to help researchers out with the bioprospection of potentially new AChEi.
format Online
Article
Text
id pubmed-6201143
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-62011432018-11-07 Naturally Occurring Acetylcholinesterase Inhibitors and Their Potential Use for Alzheimer's Disease Therapy dos Santos, Thaiane Coelho Gomes, Thaís Mota Pinto, Bruno Araújo Serra Camara, Adriana Leandro Paes, Antonio Marcus de Andrade Front Pharmacol Pharmacology Alzheimer's disease (AD) is a main cause of dementia, accounting for up to 75% of all dementia cases. Pathophysiological processes described for AD progression involve neurons and synapses degeneration, mainly characterized by cholinergic impairment. This feature makes acetylcholinesterase inhibitors (AChEi) the main class of drugs currently used for the treatment of AD dementia phase, among which galantamine is the only naturally occurring substance. However, several plant species producing diverse classes of alkaloids, coumarins, terpenes, and polyphenols have been assessed for their anti-AChE activity, becoming potential candidates for new anti-AD drugs. Therefore, this mini-review aimed to recapitulate last decade studies on the anti-AChE activity of plant species, their respective extracts, as well as isolated compounds. The anti-AChE activity of extracts prepared from 54 plant species pertaining 29 families, as well as 36 isolated compounds were classified and discussed according to their anti-AChE pharmacological potency to highlight the most prominent ones. Besides, relevant limitations, such as proper antioxidant assessment, and scarcity of toxicological and clinical studies were also discussed in order to help researchers out with the bioprospection of potentially new AChEi. Frontiers Media S.A. 2018-10-18 /pmc/articles/PMC6201143/ /pubmed/30405413 http://dx.doi.org/10.3389/fphar.2018.01192 Text en Copyright © 2018 Santos, Gomes, Pinto, Camara and Paes. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
dos Santos, Thaiane Coelho
Gomes, Thaís Mota
Pinto, Bruno Araújo Serra
Camara, Adriana Leandro
Paes, Antonio Marcus de Andrade
Naturally Occurring Acetylcholinesterase Inhibitors and Their Potential Use for Alzheimer's Disease Therapy
title Naturally Occurring Acetylcholinesterase Inhibitors and Their Potential Use for Alzheimer's Disease Therapy
title_full Naturally Occurring Acetylcholinesterase Inhibitors and Their Potential Use for Alzheimer's Disease Therapy
title_fullStr Naturally Occurring Acetylcholinesterase Inhibitors and Their Potential Use for Alzheimer's Disease Therapy
title_full_unstemmed Naturally Occurring Acetylcholinesterase Inhibitors and Their Potential Use for Alzheimer's Disease Therapy
title_short Naturally Occurring Acetylcholinesterase Inhibitors and Their Potential Use for Alzheimer's Disease Therapy
title_sort naturally occurring acetylcholinesterase inhibitors and their potential use for alzheimer's disease therapy
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6201143/
https://www.ncbi.nlm.nih.gov/pubmed/30405413
http://dx.doi.org/10.3389/fphar.2018.01192
work_keys_str_mv AT dossantosthaianecoelho naturallyoccurringacetylcholinesteraseinhibitorsandtheirpotentialuseforalzheimersdiseasetherapy
AT gomesthaismota naturallyoccurringacetylcholinesteraseinhibitorsandtheirpotentialuseforalzheimersdiseasetherapy
AT pintobrunoaraujoserra naturallyoccurringacetylcholinesteraseinhibitorsandtheirpotentialuseforalzheimersdiseasetherapy
AT camaraadrianaleandro naturallyoccurringacetylcholinesteraseinhibitorsandtheirpotentialuseforalzheimersdiseasetherapy
AT paesantoniomarcusdeandrade naturallyoccurringacetylcholinesteraseinhibitorsandtheirpotentialuseforalzheimersdiseasetherapy